Publication: Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis
| dc.contributor.authors | Arman, A.; Yilmaz, B.; Coker, A.; Inanc, N.; Direskeneli, H. | |
| dc.date.accessioned | 2022-03-12T17:19:41Z | |
| dc.date.accessioned | 2026-01-11T15:15:17Z | |
| dc.date.available | 2022-03-12T17:19:41Z | |
| dc.date.issued | 2006 | |
| dc.description.abstract | Objective Interleukin I (IL-1) family is composed of two agonists, IL-1 alpha and IL-1 beta and IL-1 receptor antagonist, IL-1Ra. The purpose of this study was to determine the relationship between polymorphisms of IL-1 receptor antagonist (IL-1RN), IL-1B promoter and IL-1B exon 5 genes and susceptibility to rheumatoid arthritis (RA) in Turkish population. Methods Polymerase chain reaction (PCR) was used to determine the genotype of the IL-1RN for 94 RA patients and 104 healthy controls. Genotyping of IL-1B polymorphisms at positions -511 (C/T) and +3953 (C/T) was detected by PCR followed restriction fragment length analysis. Results There was no significant difference in IL-1RN genotype and allele distributions between RA and the control groups. In addition, no significant association was observed in the allelic frequency (C or T) of IL-1B promoter (-511) between RA patients and the controls (P = 0,118), but the genotype distribution of 1/2 (C/T) at position -511 showed a significant difference (P = 0,038). Also, 2/2 genotype (T/T); (P = 0,028), and allele 2 (T) distribution (P = 0,011) of IL-1B (+3953) showed significant differences between RA patients and the control groups in the study population. Conclusion These results imply that 2/2 (T/T) genotype or allele 2 (T) of IL-B (+3953) are susceptibility factors for RA in Turkey. Also, 1/2 genotype (C/T) of IL-1 -511 can play a protective role for RA. | |
| dc.identifier.doi | doiWOS:000243516500006 | |
| dc.identifier.eissn | 1593-098X | |
| dc.identifier.issn | 0392-856X | |
| dc.identifier.pubmed | 17207379 | |
| dc.identifier.uri | https://hdl.handle.net/11424/228141 | |
| dc.identifier.wos | WOS:000243516500006 | |
| dc.language.iso | eng | |
| dc.publisher | CLINICAL & EXPER RHEUMATOLOGY | |
| dc.relation.ispartof | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | 1L-1B and IL-1RN polymorphism | |
| dc.subject | rheumatoid arthritis | |
| dc.subject | SYSTEMIC-LUPUS-ERYTHEMATOSUS | |
| dc.subject | DISEASE-ACTIVITY | |
| dc.subject | TANDEM REPEAT | |
| dc.subject | PLASMA-LEVELS | |
| dc.subject | ASSOCIATION | |
| dc.subject | POPULATION | |
| dc.subject | IL-1-BETA | |
| dc.subject | SECRETION | |
| dc.subject | SEVERITY | |
| dc.subject | TURKEY | |
| dc.title | Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 648 | |
| oaire.citation.issue | 6 | |
| oaire.citation.startPage | 643 | |
| oaire.citation.title | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | |
| oaire.citation.volume | 24 |
